stockrowVoyager Therapeutics, Inc.
VYGR Healthcare Biotechnology
Voyager Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.4 million, down 49.5% from fiscal 2024.
- Revenue
- −70.0%
- EPS
- +14.9%
- Free cash flow
- +37.1%
Quarter to September 2026, against a year earlier
Follow VYGR
Alert me
Voyager Therapeutics, Inc. (VYGR) EV/Sales
As of 6 November 2026, Voyager Therapeutics, Inc. (VYGR) trades at a EV/Sales of 0.4×. Over the past ten years it has ranged from −9.1× (March 2016) to 89.7× (October 2017); the current reading is higher than 26% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.8× | 12.43% |
| FY2024 | 0.8× | 20.54% |
| FY2023 | 0.6× | (77.41%) |
| FY2022 | 2.8× | — |
| FY2021 | −0.8× | — |
| FY2020 | 0.5× | (76.53%) |
| FY2019 | 2.1× | (89.01%) |
| FY2018 | 19.1× | (36.18%) |
| FY2017 | 29.9× | 231.53% |
| FY2016 | 9.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 2.3× | (15.45%) |
| Jun 2026 | 2.8× | 14.80% |
| Mar 2026 | 2.4× | 185.16% |
| Dec 2025 | 0.8× | (59.60%) |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OTLK Outlook Therapeutics, Inc. compare | −66.1× |
| NBP NovaBridge Biosciences compare | −5.3× |
| AVXL Anavex Life Sciences Corp. compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HURA TuHURA Biosciences, Inc. compare | n/m |
| OKUR OnKure Therapeutics, Inc. compare | n/m |
| VYGR Voyager Therapeutics, Inc. | 0.4× |
| HUMA Humacyte, Inc. compare | 41.4× |
| ANIX ANIXA BIOSCIENCES INC compare | 101× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)